The combination of e-cigarettes containing nicotine and 12 weeks of counseling can help smokers quit more effectively than counseling alone.

Transcatheter aortic valve replacement (TAVR) outcomes have been worse than expected for 11% of healthcare providers in the United States, according to a new analysis of data from 2015 to 2017.

Transcatheter aortic valve replacement (TAVR) procedures with a self-expanding artificial valve are “very viable and safe” for low-risk patients with a bicuspid aortic valve, according to new research that tracked the outcomes of 150 patients.

Of COVID-19 patients who develop serious heart complications, most don’t see this problem until late in the disease’s progression. However, some are turning up with extensive heart inflammation at the outset.

Physicians at St. Michael’s Hospital of Unity Health Toronto in Canada announced this month that they’d completed the world’s first minimally invasive tricuspid valve replacement with success.

Mount Sinai has launched an Adult Congenital Heart Disease Center at Mount Sinai Heart in New York in an attempt to streamline CHD care throughout the life cycle.

A study published in JACC: Cardiovascular Interventions this month found that patients who suffer from migraines may find long-term relief after transcatheter patent foramen ovale closure.

The largest comprehensive study of congenital heart disease to date has revealed that, despite an overall decline in mortality over the past few decades, a child’s odds of surviving a CHD diagnosis hinge on the economic health of their community.

An analysis of PARTNER 2 data published in the New England Journal of Medicine Jan. 29 suggests five-year post-op outcomes are similar among heart patients who undergo either transcatheter or surgical aortic valve replacement.

Injection drug users prescribed controlled release hydromorphone—an opioid—are three times more likely to develop endocarditis than users prescribed other opioids, according to work published Jan. 22 in The Lancet Infectious Diseases.

Palo Alto, Calif.-based nonprofit Additional Ventures announced Jan. 21 it would be awarding a total of $5.7 million to five institutions for research on single ventricle heart defects.

Redesigning the artificial heart valve could improve blood flow and potentially eliminate the need for blood thinners in patients with mechanical support, according to a new study.